- Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025
- Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024 conference call
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) — Standard BioTools Inc. (Standard BioTools or the Company) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while supporting the execution of the Companys long-term strategic plan.
Following the completion of the SomaLogic merger, our management team has conducted a comprehensive review of our business as we continue to execute our strategic growth plan. Today we a…
Read the full article at: https://www.globenewswire.com/news-release/2024/04/25/2869611/0/en/Standard-BioTools-Announces-Operational-Restructuring-Plan-to-Drive-Long-Term-Profitable-Growth.html